The central role of TNFα in many disease states has identified this cytokine as an important therapeutic target to counteract vascular inflammation (Sedger and McDermott, 2014; Esposito and Cuzzocrea, 2009) and several TNFα blockers have been approved by the FDA and have been effective for the suppression of immune-system diseases, such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis (Ackerman et al., 2016). Here, TNF is linked to Crohn disease.